Marco Boorsma
General Partner @ Forbion Capital Partners
Naarden, The Netherlands
Marco Boorsma is a Series A investor at Forbion Capital Partners in Naarden focused on Biotechnology and Health Care. Marco Boorsma is based out of Amsterdam, Noord-Holland, and is the General Partner of Forbion and a Board of Director at Corsera Health. Marco previously worked at VectorY as a Board Director. Marco Boorsma attended the University of Groningen.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Marco Boorsma invests in
Stages Marco Boorsma invests in
Countries Marco Boorsma invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (56%)
- Health Care 5 (31%)
- Pharmaceutical 5 (31%)
- Medical 4 (25%)
- Therapeutics 4 (25%)
Stage
- Series A 5 (31%)
- Series B 5 (31%)
- Series C 4 (25%)
- Seed 1 (6%)
- Series D 1 (6%)
Country
- United States 4 (25%)
- Canada 2 (13%)
- Norway 1 (6%)
- Denmark 1 (6%)
- Ireland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing theproduction of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment. | $80M / Series A / Jan 07, 2026 | ||
| Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | $93.5M / Series A / Jan 06, 2025 | ||
| Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | $28.1M / Seed / Feb 29, 2024 | ||
| Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These include novel therapeutic candidates that fulfill unmet clinical needs across a spectrum of diseases. | $81.4M / Series A / Jan 23, 2024 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | ||
| NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M / Series C / Dec 17, 2021 | ||
| Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas. | $100M / Series A / Oct 14, 2021 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M / Series B / Sep 08, 2020 | ||
| Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's,Alzheimer's, atherosclerosis, and type 2 diabetes.The company was incorporated in 2016 and is headquartered in Dublin, Ireland. | $45.8M / Series B / Nov 19, 2018 | ||
| Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $80M / Series D / Oct 25, 2018 | ||
| See all 16 investments → | |||
Co-Investors
About Forbion Capital Partners
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Forbion Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joy Faucher
General Partner
|
|||
|
Marco Boorsma
General Partner
|
|||
Nanna Lüneborg
General Partner
|
|||
Onno Stolpe
Venture Partner
|
|||
Sander Slootweg
Managing Partner and co-founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marco Boorsma invest in?
Marco Boorsma invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Marco Boorsma?
Public channels for Marco Boorsma include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Marco Boorsma last invest?
The most recent investment recorded for Marco Boorsma closed in Jan 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
